Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients
Upadacitinib could be an additional safe and effective treatment for treating refractory palmoplantar pustulosis with a potential benefit on patients' quality of life. Further studies are needed to assess its short-and long-term efficacy and safety in larger sample sizes in randomized double-blind controlled trials.
Authors
- Jingyi Yang (ORCID: https://orcid.org/0000-0002-9781-7054)
- Na Du (ORCID: https://orcid.org/0000-0002-4383-2451)
- Min Wei (ORCID: https://orcid.org/0000-0003-0237-7955)
- Yiwen Zhang (ORCID: https://orcid.org/0000-0002-5232-0335)
- Lei Cao
- Xinyan Lv (ORCID: https://orcid.org/0009-0004-2564-1610)
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2024-11-06
- DOI
- https://doi.org/10.3389/fmed.2024.1476793
- Citations
- 12
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.89